Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Active Trials
    0(0%)

    Phase Distribution

    Phase 1
    1
    17%
    Phase 2
    5
    83%

    Phase Distribution

    1

    Early Stage

    5

    Mid Stage

    0

    Late Stage

    Phase Distribution6 total trials
    Phase 1Safety & dosage
    1(16.7%)
    Phase 2Efficacy & side effects
    5(83.3%)

    Highest Phase Reached

    Phase 2

    Trial Status & Enrollment

    Completion Rate

    0.0%

    0 of 6 finished

    Non-Completion Rate

    100.0%

    6 ended early

    Currently Active

    0

    trials recruiting

    Total Trials

    6

    all time

    Status Distribution
    Terminated(6)

    Detailed Status

    Withdrawn6

    Development Timeline

    Analytics

    Development Status

    Total Trials
    6
    Active
    0
    Success Rate
    N/A
    Most Advanced
    Phase 2

    Trials by Phase

    Phase 11 (16.7%)
    Phase 25 (83.3%)

    Trials by Status

    withdrawn6100%

    Recent Activity

    0 active trials
    Showing 5 of 6
    withdrawnphase_2

    Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

    NCT00227773
    withdrawnphase_2

    Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer

    NCT00253526
    withdrawnphase_1

    Monoclonal Antibody Therapy in Treating Patients With Advanced Solid Tumors

    NCT00052403
    withdrawnphase_2

    S0212 Celecoxib in Treating Patients With High-Grade Squamous Intraepithelial Lesions of the Cervix

    NCT00072540
    withdrawnphase_2

    Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma

    NCT00112879
    View all 6 trials

    Clinical Trials (6)

    Showing 6 of 6 trials
    NCT00227773Phase 2

    Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

    Withdrawn
    NCT00253526Phase 2

    Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer

    Withdrawn
    NCT00052403Phase 1

    Monoclonal Antibody Therapy in Treating Patients With Advanced Solid Tumors

    Withdrawn
    NCT00072540Phase 2

    S0212 Celecoxib in Treating Patients With High-Grade Squamous Intraepithelial Lesions of the Cervix

    Withdrawn
    NCT00112879Phase 2

    Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma

    Withdrawn
    NCT00025051Phase 2

    Celecoxib in Preventing Skin Cancer

    Withdrawn

    All 6 trials loaded

    Drug Details

    Intervention Type
    Procedure
    Total Trials
    6